Altre lingue EirGenix Inc.

Azioni

6589

TW0006589005

Prezzo di chiusura Taipei Exchange Altri mercati azionari 00:00:00 20/05/2024			Variaz. 5gg	Var. 1 gen.
82,5 ^TWD	-0,72%		+2,87%	-17,91%

22/03	EirGenix Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
08/03	EirGenix, Inc. delibera di firmare il contratto con la CRO clinica e le aziende interessate per il percorso clinico di Fase III dell'EG1206A	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	08/03
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	23/11
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	09/11
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	18/09/23
Novartis : avis favorable pour un biosimilaire du trastuzumab	18/09/23
Novartis-Krebsmedikament Trastuzumab erhält EMA-Empfehlung	18/09/23
Sandoz décroche un avis positif du CHMP pour le trastuzumab	18/09/23
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency	18/09/23
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	18/09/23
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	18/09/23
Sandoz erhält positive CHMP-Stellungnahme für Krebs-Biosimilar	18/09/23
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	03/05/23
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23
EirGenix Inc. announced a financing transaction	10/03/23
EirGenix Inc. Announces Executive Changes	10/01/23
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	28/12/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue EirGenix Inc.

Azioni

6589

TW0006589005

Altre lingue

Filtri